Literature DB >> 11034959

Influence of menstrual and reproductive factors on ovarian cancer risk in women with and without family history of breast or ovarian cancer.

A Tavani1, E Ricci, C La Vecchia, M Surace, G Benzi, F Parazzini, S Franceschi.   

Abstract

BACKGROUND: As women with a family history of ovarian and/or breast cancer possibly inherit genetic changes that alter their risk of ovarian cancer, other established risk factors for ovarian cancer may influence the risk differently in women with and without a family history of the disease.
METHODS: Case-control study conducted between 1983 and 1991 in Northern Italy. Cases were 971 women, under 75 years, with incident, histologically confirmed epithelial ovarian cancer, and controls were 2758 women, under 75 years, admitted to hospitals for non-malignant, non-hormone-related conditions, who had not undergone bilateral oophorectomy. Of these, 93 cases and 139 controls had a family history of ovarian and/or breast cancer.
RESULTS: The risk of ovarian cancer increased with irregular menstrual cycles, late age at menopause, natural menopause, nulliparity, never use of oral contraceptives and use of hormone replacement therapy. We computed an 'adult life risk score' (ALRS) considering the combined effect of these factors. Compared to women without a family history and a low ALRS, the OR was 1.7 for women without family history and high ALRS, 1.4 for women with a family history and low ALRS, and 3.5 for women with a family history and high ALRS.
CONCLUSIONS: Intervention on selected hormonal risk factors for ovarian cancer might be important for women with a family history of the disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11034959     DOI: 10.1093/ije/29.5.799

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  10 in total

1.  Hormone replacement therapy for the primary prevention of chronic diseases: recommendation statement from the Canadian Task Force on Preventive Health Care.

Authors:  C Nadine Wathen; Denice S Feig; John W Feightner; Beth L Abramson; Angela M Cheung
Journal:  CMAJ       Date:  2004-05-11       Impact factor: 8.262

2.  Luteinizing hormone compromises the in vivo anti-tumor effect of cisplatin on human epithelial ovarian cancer cells.

Authors:  Yan Huang; Yuqi Zhou; Lingfang Xia; Jia Tang; Hao Wen; Meiqin Zhang
Journal:  Oncol Lett       Date:  2017-12-19       Impact factor: 2.967

3.  Features of ovarian cancer in Lynch syndrome (Review).

Authors:  Kanako Nakamura; Kouji Banno; Megumi Yanokura; Miho Iida; Masataka Adachi; Kenta Masuda; Arisa Ueki; Yusuke Kobayashi; Hiroyuki Nomura; Akira Hirasawa; Eiichiro Tominaga; Daisuke Aoki
Journal:  Mol Clin Oncol       Date:  2014-08-20

4.  Menstrual bleeding patterns among regularly menstruating women.

Authors:  Sonya S Dasharathy; Sunni L Mumford; Anna Z Pollack; Neil J Perkins; Donald R Mattison; Jean Wactawski-Wende; Enrique F Schisterman
Journal:  Am J Epidemiol       Date:  2012-02-20       Impact factor: 4.897

5.  The impact of workplace psychosocial factors on menstrual disorders and infertility: a protocol for a systematic review and meta-analysis.

Authors:  Natsu Sasaki; Kotaro Imamura; Kazuhiro Watanabe; Yui Hidaka; Emiko Ando; Hisashi Eguchi; Akiomi Inoue; Kanami Tsuno; Yu Komase; Mako Iida; Yasumasa Otsuka; Asuka Sakuraya; Yumi Asai; Mai Iwanaga; Yuka Kobayashi; Reiko Inoue; Akihito Shimazu; Akizumi Tsutsumi; Norito Kawakami
Journal:  Syst Rev       Date:  2022-09-07

6.  Menses resumption after cancer treatment-induced amenorrhea occurs early or not at all.

Authors:  Melanie H Jacobson; Ann C Mertens; Jessica B Spencer; Amita K Manatunga; Penelope P Howards
Journal:  Fertil Steril       Date:  2015-12-01       Impact factor: 7.329

7.  Reproductive factors for ovarian cancer in southern Chinese women.

Authors:  Maria Pasalich; Dada Su; Colin W Binns; Andy H Lee
Journal:  J Gynecol Oncol       Date:  2013-04-05       Impact factor: 4.401

8.  Menopausal Hormone Replacement Therapy and the Risk of Ovarian Cancer: A Meta-Analysis.

Authors:  Yang Liu; Lan Ma; Xiaoling Yang; Jia Bie; Dongya Li; Chunyi Sun; Jie Zhang; Yushi Meng; Jie Lin
Journal:  Front Endocrinol (Lausanne)       Date:  2019-12-03       Impact factor: 5.555

9.  Follicle-stimulating hormone inhibits apoptosis in ovarian cancer cells by regulating the OCT4 stem cell signaling pathway.

Authors:  Zhenbo Zhang; Yaping Zhu; Yunli Lai; Xiaomei Wu; Zhengzhong Feng; Yinhua Yu; Robert C Bast; Xiaoping Wan; Xiaowei Xi; Youji Feng
Journal:  Int J Oncol       Date:  2013-08-06       Impact factor: 5.650

10.  Prevention of chemotherapy-induced premature ovarian insufficiency in mice by scaffold-based local delivery of human embryonic stem cell-derived mesenchymal progenitor cells.

Authors:  Eun-Young Shin; Da-Seul Kim; Min Ji Lee; Ah Reum Lee; Sung Han Shim; Seung Woon Baek; Dong Keun Han; Dong Ryul Lee
Journal:  Stem Cell Res Ther       Date:  2021-07-31       Impact factor: 6.832

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.